Noriyuki Masuda, MD, PhD | Authors

Establishment of the Standard Regimen for Non-Small- Cell Lung Cancer in Japan

January 01, 2001

Preclinical data suggest that irinotecan (Camptosar, CPT-11), a novel topoisomerase I inhibitor, has exhibited promising activity in the treatment of lung cancer. In a phase II study of non-small-cell lung cancer, irinotecan

Irinotecan in Small-Cell Lung Cancer-Japanese Trials

July 02, 2000

Irinotecan has appeared to have significant activity against previously treated and untreated small-cell lung cancer (SCLC). The major toxicities of irinotecan are neutropenia and diarrhea, although there is interpatient